The development of 3-(4-hydroxyphenyl)indoline-2-ones and other strategies for the treatment of cancer

Boudreau, Matthew W.

Permalink

https://hdl.handle.net/2142/115658 Copy

Description

Title

The development of 3-(4-hydroxyphenyl)indoline-2-ones and other strategies for the treatment of cancer

Author(s)

Boudreau, Matthew W.

Issue Date

2022-02-28

Director of Research (if dissertation) or Advisor (if thesis)

Hergenrother, Paul J

Doctoral Committee Chair(s)

Hergenrother, Paul J

Committee Member(s)

• Burke, Martin D
• Mitchell, Douglas A
• Fan, Timothy M

Department of Study

Chemistry

Discipline

Chemistry

Degree Granting Institution

University of Illinois at Urbana-Champaign

Degree Name

Ph.D.

Degree Level

Dissertation

Keyword(s)

• cancer
• drug development

Abstract

Over the past century, our ability to develop new targeted anticancer strategies has ushered in a new era in cancer treatment that has greatly evolved from the radical surgery and highly toxic campaigns of the past. Often common in anticancer small molecule development is a complex history outlining how chemical matter was first identified, derivatized, and utilized to ultimately arrive at exciting molecules for drug development. Herein, the history and our current journey of one such developing anticancer scaffold, the 3-(4-hydroxyphenyl)indoline-2-ones, is reviewed. With humble beginnings in 19th century Bavaria to recent interest in its tumor eradication of drug-resistant breast cancer, 3-(4-hydroxyphenyl)indoline-2-ones are an intriguing anticancer pharmacophore. Specifically, we describe our discovery of ErSO, a 3-(4-hydroxyphenyl)indoline-2-one that induces estrogen receptor alpha-positive (ERα)-dependent death of breast cancer cells through a mechanism distinct from clinically approved ERα drugs, namely hyperactivation of the anticipatory unfolded protein response (a-UPR). ErSO has remarkable activity in multiple ERα-positive tumor models, with several examples of complete tumor eradication without recurrence. While ErSO has tremendous promise as a new drug to target ERα-positive breast cancer, we also report herein the discovery of second-generation derivatives, ErSO-DFP and ErSO-TFPy, which have even more promising targeted anticancer activities. Unrelated to 3-(4-hydroxyphenyl)indoline-2-ones research, a variety of other ongoing anticancer projects being developed in the Hergenrother laboratory (PAC-1 and IB-DNQ) are described.

Graduation Semester

2022-05

Type of Resource

Thesis

Copyright and License Information

Copyright 2022 Matthew W. Boudreau

Owning Collections